Effects of agents targeting glutamatergic systems on marble-burying behavior

Neuroscience Letters

Volumn 471, Issue 2, 2010, Pages 63-65

  Iijima, Michihiko ^a   Kurosu, Shinsuke ^a   Chaki, Shigeyuki ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

AMPA receptor; Glutamatergic systems; Marble burying behavior; NR2B receptor

Indexed keywords

1,4 BENZODIOXAN 6 CARBOXYLIC ACID PIPERIDIDE; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; GLUTAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CONTROL; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG TARGETING; LOCOMOTION; MALE; MOUSE; NEUROMODULATION; NEUROPSYCHOLOGICAL TEST; NEUROTRANSMISSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; TASK PERFORMANCE;

ANIMALS; BEHAVIOR, ANIMAL; DIOXOLES; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; PHENOLS; PIPERIDINES; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 75949084436     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.12.048     Document Type: Article

References (28)

1. Abe M., Nakai H., Tabata R., Saito K., and Egawa M. Effect of 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]propoxy]-1,3-benzodioxole HCl (MKC-242), a novel 5-HT1A-receptor agonist, on aggressive behavior and marble burying behavior in mice. Jpn. J. Pharmacol. 76 (1998) 297-304
2. Arnold P.D., Rosenberg D.R., Mundo E., Tharmalingam S., Kennedy J.L., and Richter M.A. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl.) 174 (2004) 530-538
3. Arnold P.D., Sicard T., Burroughs E., Richter M.A., and Kennedy J.L. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch. Gen. Psychiatry 63 (2006) 769-776
4. Broekkamp C.L., and Jenck F. The relationship between various animal models of anxiety, fear-related psychiatric symptoms and response to serotonergic drugs. In: Bevan P., Cools R., and Archer T. (Eds). Behavioral Pharmacology of 5-HT (1989), Erlbaum, Hillsdale 321-335
5. Chaki S., Hirota S., Funakoshi T., Suzuki Y., Suetake S., Okubo T., Ishii T., Nakazato A., and Okuyama S. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor. J. Pharmacol. Exp. Ther. 304 (2003) 818-826
6. Chakrabarty K., Bhattacharyya S., Christopher R., and Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30 (2005) 1735-1740
7. Coric V., Taskiran S., Pittenger C., Wasylink S., Mathalon D.H., Valentine G., Saksa J., Wu Y.T., Gueorguieva R., Sanacora G., Malison R.T., and Krystal J.H. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol. Psychiatry 58 (2005) 424-428
8. D'Ascenzo M., Fellin T., Terunuma M., Revilla-Sanchez R., Meaney D.F., Auberson Y.P., Moss S.J., and Haydon P.G. mGluR5 stimulates gliotransmission in the nucleus accumbens. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 1995-2000
9. Davidson J., and Bjorgvinsson T. Current and potential pharmacological treatments for obsessive-compulsive disorder. Exp. Opin. Investig. Drugs 12 (2003) 993-1001
10. Dekeyne A., Mannoury la Cour C., Gobert A., Brocco M., Lejeune F., Serres F., Sharp T., Daszuta A., Soumier A., Papp M., Rivet J.M., Flik G., Cremers T.I., Muller O., Lavielle G., and Millan M.J. S3 a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology (Berl.) 199 2008 (2006) 549-568
11. Dickel D.E., Veenstra-VanderWeele J., Cox N.J., Wu X., Fischer D.J., Van Etten-Lee M., Himle J.A., Leventhal B.L., Cook Jr. E.H., and Hanna G.L. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch. Gen. Psychiatry 63 (2006) 778-785
12. Du J., Suzuki K., Wei Y., Wang Y., Blumenthal R., Chen Z., Falke C., Zarate Jr. C.A., and Manji H.K. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 32 (2007) 793-802
13. Egashira N., Okuno R., Harada S., Matsushita M., Mishima K., Iwasaki K., Nishimura R., Oishi R., and Fujiwara M. Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Eur. J. Pharmacol. 586 (2008) 164-170
14. Grant P., Lougee L., Hirschtritt M., and Swedo S.E. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J. Child. Adolesc. Psychopharmacol. 17 (2007) 761-767
15. Ichimaru Y., Egawa T., and Sawa A. 5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn. J. Pharmacol. 68 (1995) 65-70
16. Kaplan A., and Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr. Serv. 54 (2003) 1111-1118
17. Karasawa J., Shimazaki T., Kawashima N., and Chaki S. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res. 1042 (2005) 92-98
18. Mancebo M.C., Eisen J.L., Pinto A., Greenberg B.D., Dyck I.R., and Rasmussen S.A. The brown longitudinal obsessive compulsive study: treatments received and patient impressions of improvement. J. Clin. Psychiatry 67 (2006) 1713-1720
19. Njung'e K., and Handley S.L. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol. Biochem. Behav. 38 (1991) 63-67
20. Preskorn S.H., Baker B., Kolluri S., Menniti F.S., Krams M., and Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 28 (2008) 631-637
21. Rosenberg D.R., MacMaster F.P., Keshavan M.S., Fitzgerald K.D., Stewart C.M., and Moore G.J. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J. Am. Acad. Child. Adolesc. Psychiatry 39 (2000) 1096-1103
22. Rosenberg D.R., Mirza Y., Russell A., Tang J., Smith J.M., Banerjee S.P., Bhandari R., Rose M., Ivey J., Boyd C., and Moore G.J. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J. Am. Acad. Child. Adolesc. Psychiatry 43 (2004) 1146-1153
23. Sano Y., Ornthanalai V.G., Yamada K., Homma C., Suzuki H., Suzuki T., Murphy N.P., and Itohara S. X11-like protein deficiency is associated with impaired conflict resolution in mice. J. Neurosci. 29 (2009) 5884-5896
24. Shigemoto R., Kinoshita A., Wada E., Nomura S., Ohishi H., Takada M., Flor P.J., Neki A., Abe T., Nakanishi S., and Mizuno N. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J. Neurosci. 17 (1997) 7503-7522
25. Shimazaki T., Iijima M., and Chaki S. Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test. Eur. J. Pharmacol. 501 (2004) 121-125
26. Spooren W.P., Vassout A., Neijt H.C., Kuhn R., Gasparini F., Roux S., Porsolt R.D., and Gentsch C. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther. 295 (2000) 1267-1275
27. Tigaret C.M., Thalhammer A., Rast G.F., Specht C.G., Auberson Y.P., Stewart M.G., and Schoepfer R. Subunit dependencies of N-methyl-d-aspartate (NMDA) receptor-induced alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor internalization. Mol. Pharmacol. 69 (2006) 1251-1259
28. Whiteside S.P., Port J.D., Deacon B.J., and Abramowitz J.S. A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety. Psychiatry Res. 146 (2006) 137-147